A phase III double blind, clinical endpoint study of REMUNE to evaluate HIV disease progression, AIDS or death.

Trial Profile

A phase III double blind, clinical endpoint study of REMUNE to evaluate HIV disease progression, AIDS or death.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs GP120-depleted HIV-1 vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2017 Based upon a recommendation from the Data Safety Management Board (DSMB), this study 806 was terminated in May 1999.
    • 23 Feb 2017 New trial record
    • 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top